Login to Your Account

New Name, Money: Metabolex’s Gout Drug Advances at Cymabay

By Jennifer Boggs
Managing Editor

Tuesday, December 3, 2013
Three years ago, Metabolex Inc. seemed on the road to success, with a promising gout drug reporting Phase II data and three pharma partnerships inked in quick succession. But then partner Sanofi SA dropped out of a diabetes deal in 2011 and for two years the Hayward, Calif.-based biotech appeared to go dormant.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription